GLP‑1s and liver health

GLP-1 drugs work by mimicking a gut hormone that helps control blood sugar and appetite. Doctors are now using that same class to treat some forms of fatty liver disease, including metabolic dysfunction-associated steatohepatitis, or MASH. (ajmc.com) MASH is the inflamed, scarring form of metabolic dysfunction-associated steatotic liver disease, or MASLD, a condition marked by excess fat in the liver. A 2025 review in *JAMA* called MASLD the most common liver disease worldwide and estimated adult prevalence at about 30%. (jamanetwork.com) The shift from theory to practice came in 2025. On August 15, 2025, the U.S. Food and Drug Administration approved Wegovy, the 2.4-mg semaglutide injection, for adults with MASH and moderate-to-advanced fibrosis who do not have cirrhosis. (fda.gov) That approval leaned on the phase 3 ESSENCE trial. In a planned 72-week analysis of the first 800 patients, 62.9% on semaglutide had resolution of steatohepatitis without worsening fibrosis, versus 34.3% on placebo; 36.8% had fibrosis improvement without worsening steatohepatitis, versus 22.4% on placebo. (abom.org) Researchers are also testing whether semaglutide helps the liver directly, not just through weight loss. A report highlighted this week said semaglutide improved liver health markers even in patients who did not lose weight, pointing to effects inside liver tissue as well as effects on the scale. (knowridge.com) That matters in clinic because liver disease treatment has long depended on weight loss targets many patients struggle to reach and maintain. The American Journal of Managed Care reported on April 16, 2026, that clinicians are increasingly weighing GLP-1 drugs as liver therapies, not only diabetes or obesity drugs. (ajmc.com) Professional guidance has already started to catch up. The American Association for the Study of Liver Diseases said on November 7, 2025, that its updated guidance gives clinicians recommendations on selecting patients with MASH and stage F2-F3 fibrosis for semaglutide and on monitoring safety and response. (aasld.org) The liver story does not erase the tradeoffs. FDA said the semaglutide label for MASH still carries the drug’s established warnings and common side effects, including gastrointestinal symptoms, and the indication is tied to diet and physical activity. (fda.gov) So the same weekly injections that became famous for weight loss are being recast as liver medicines. The next question is no longer whether GLP-1s touch liver disease, but which patients benefit most and how broadly doctors will use them. (ajmc.com)